In-silico personalized protein–protein interaction networks prioritize candidate compounds for glioblastoma

The incidence of cancer continues to rise globally, with many tumor types remaining difficult to treat effectively. While existing drugs can alleviate symptoms or slow disease progression, their efficacy varies considerably between patients. To explore this challenge, we present a computational app